turn on
    Mobile finance
    Open APP registered log in

    Home >Stock channel > text

    Xiumeile has sold the world's number one for 7 consecutive years. The potential market space is huge (with stocks)

    2019-02-11 06:52:35

    Financial sector website 

    What is the best medicine in the world? Is the plate blue root that 1.3 billion people often drink when they catch a cold? Or is it the red Gleevec in "I am not a drug god"? The answer is a drug that most people are not familiar with - Humira (Chinese name "Xiu Meile"). The product is a variety of international pharmaceutical giant AbbVie (Aibowei), its latest published 2018 financial report shows that Xiu Meile's 2018 sales of 134.46 billion yuan, set a record annual sales of a single drug. Since 2012, Xiu Meile has been ranked first in the global drug sales rankings.

    The main name of Xia Mei Le is “Adalimumab Injection”. The reason why it has been ranked first in the world for 7 consecutive years is called “King of Medicine”. The key reason is that it can treat many diseases, and most of these diseases are A condition that is difficult to treat. Since its listing, it has been approved for the treatment of 14 diseases including rheumatoid arthritis, ankylosing spondylitis and psoriasis in the United States and the European Union. It is mainly targeted at rheumatoid arthritis and mandatory spondylitis, which are currently two diseases that are more common in the world and are more difficult to cure. At present, the total number of patients with rheumatoid arthritis and mandatory spondylitis in China is about 10 million, and the potential market space is huge.

    In the A-share company:

    Jingfeng Pharmaceutical: The wholly-owned subsidiary Shanghaifengfeng Pharmaceutical has its own research and development technology of adalimumab injection (recombinant human anti-TNF-a monoclonal antibody injection).

    Hisun Pharmaceutical: The application for the listing of adalimumab injection has been submitted to the State Drug Administration.

    Hualan Bio: Participating company Hualan Genetic Engineering Co., Ltd. has obtained the clinical trial approval for adalimumab injection.

    Hot searchXiu Mei Le

    Editor in charge: Zhou Zhuang RF12883

                    Must not look

    Wonderful recommendation

    Important announcement of the listed company on Monday

    02-11 18:00

    Negative: US companies apply for a 337 investigation into Yongan Pharmaceutical Taurine products

    02-11 17:51

    High proportion of dividends to send stocks can be expected. These 15 shares may become "high to send new favors"

    02-11 13:58

    Chinese medicine 50,000 shareholders stepping on thunder blood products AIDS antibody positive influence geometry

    02-11 06:52

    Review: The A-share opening of the Year of the Pig is up 3.53%, and the 5G concept offensive

    02-11 15:00

    Iron ore prices soared to record highs in several years

    02-11 06:45

    A-shares open the door to worry: the fundamentals of the Spring Festival leisure market are still cold

    02-11 18:08

    China's liquid metal robot development breakthroughs

    02-11 06:57

    A-share pig year opens the door. Can this sector stage the drama of "The Return of the King"?

    02-11 17:18

    Xiumeile has sold the world's number one for 7 consecutive years. The potential market space is huge (with stocks)

    02-11 06:52

                    Top Comments

    comment share it